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Original Article
The effect of Helicobacter pylori infection and
eradication in patients with gastro-oesophageal
reflux disease: A parallel-group, double-blind,
placebo-controlled multicentre study
Werner Schwizer1,2, Dieter Menne3, Kurt Schu¨tze4, Michael Vieth5,
Reiner Goergens5, Peter Malfertheiner6, Andreas Leodolter7, Michael Fried1,2
and Mark R Fox1,2,8
Abstract
Objectives: This study aimed to resolve controversy regarding the effects of Helicobacter pylori eradication therapy and H.
pylori infection in gastro-oesophageal reflux disease.
Design: A randomized, double-blind, multicentre trial was performed in patients presenting with reflux symptoms. H. pylori-
positive patients were randomized to receive either antibiotics or placebo for 7 days. H. pylori-negative patient controls
received placebo. All received esomeprazole 20mg b.d. for 7 days, followed by 40mg o.d. to complete an 8-week course, and
were followed up for 32 weeks by telephone.
Results: In this study, 198/589 (34%) patients were H. pylori-positive and 113 H. pylori-negative patients served as controls.
Baseline endoscopy revealed 63% Los Angeles grade 0A and 37% Los Angeles grade BCD oesophagitis with no difference
between patient groups. Symptom improvement on esomeprazole was seen in 89%. H. pylori eradication was successful in
82%. H. pylori eradication had no effect on symptomatic relapse (hazard ratio 1.15, 95% CI 0.74–1.8; p¼ 0.5). Overall, H. pylori-
positive patients had a lower probability of relapse compared to H. pylori-negative controls (hazard ratio 0.6, 95% CI 0.43–0.85;
p¼ 0.004). Relapse hazard was modulated also by oesophagitis grade (BCD vs. 0A, hazard ratio 2.1, 95% CI 1.5–3.0).
Conclusion: Relapse of gastro-oesophageal reflux disease symptoms after a course of high dose acid suppression took
longer for H. pylori-positive patients than H. pylori-negative controls; however eradication therapy had no effect on the risk
of relapse; ClincialTrials.gov number, NCT00574925.
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Introduction
Gastro-oesophageal reﬂux disease (GORD) is a
common medical problem with a spectrum of symp-
toms and varying degrees of severity. It is estimated
that 20–40% of the adult population experiences heart-
burn or other symptoms related to reﬂux and this can
impact on quality of life and health costs.1 Moreover,
there is a strong relation between acid reﬂux and the
development of oesophageal adenocarcinoma.2 These
concerns highlight the importance of identifying modi-
ﬁable risk factors for GORD. One such factor may be
gastric Helicobacter pylori infection.
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There is an on-going debate about the appropriate
management of H. pylori infection in GORD. Many
authors recommend H. pylori eradication prior to the
initiation of long-term proton pump inhibitor (PPI)
therapy because the combination of H. pylori and acid
suppression accelerates development of gastric mucosal
atrophy and there is some anxiety that this may increase
the risk of gastric adenocarcinoma.3 Other experts cau-
tion against this approach,4,5 as most epidemiological
studies indicate that reﬂux symptoms, mucosal disease,
and oesophageal cancer are less common in patients
with H. pylori infection.5–11 Clinical studies show that
acid suppression is more profound and the healing of
reﬂux oesophagitis during treatment with PPIs is more
rapid in patients with than in patients without gastricH.
pylori infection.12,13 Additionally, two case–control stu-
dies report an increased risk of developing GORD after
eradication of H. pylori in patients with duodenal
ulcer,14,15 although others ﬁnd no signiﬁcant
eﬀect.16–18 There are concerns, therefore, that treatment
ofH. pylori infection in GORD patients may exacerbate
the disease.
Five prospective controlled trials have studied the
eﬀects of H. pylori infection and eradication in patients
withGORD.19–23 For patients with reﬂux symptoms and
normal mucosa or grade A oesophagitis on endoscopy,
Moayyedi et al.19 observed no diﬀerence in the relapse
rate between the antibiotic, placebo, andH. pylori-nega-
tive control groups for up to 18 months of follow up.
Negative results were reported also by Kuipers et al.21
inH. pylori-positive patients with reﬂux oesophagitis. In
contrast, Schwizer et al. in a study that recruited patients
with all grades of endoscopic ﬁndings reported that H.
pylori eradication delayed the time to relapse compared
to the placebo group and H. pylori-negative controls.20
These divergent ﬁndings are likely due to diﬀerences in
patient populations or the failure to account for the pat-
tern of gastric infection and inﬂammation in the H.
pylori-positive treatment groups. The latter point may
aﬀect clinical outcomes as antral gastritis is associated
with increased acid output, whereas corpus gastritis is
associatedwith reduced acid output.24 Thus, in principle,
H. pylori eradicationmay increase or decrease acid secre-
tion and so the likelihood of acid reﬂux and related
symptoms.
This large, multicentre trial is designed to provide
more deﬁnitive evidence whether H. pylori infection
impacted on the severity or prognosis of GORD and
to inform the clinical decision whether to eradicate H.
pylori in patients presenting with reﬂux symptoms.
Subjects are stratiﬁed according to the presence and
grade of reﬂux oesophagitis at baseline to assess whether
the impact of H. pylori eradication, if any, is observed
across the spectrum of GORD. Additionally, gastric
biopsies obtained before and after treatment assess
whether the severity or pattern of gastritis, mucosal
thickness, or parietal cell numbers is related to clinical
outcome.
Methods
Erastrat is a randomized, controlled, double-blind, mul-
ticentre clinical trial of H. pylori eradication therapy in
patients presenting with typical reﬂux symptoms of at
least moderate severity as deﬁned by a score of >25 on
the Eraﬂux questionnaire.20,25 Three parallel groups are
studied. Patients in the randomized groups were H.
pylori-positive and assigned to eradication treatment
or placebo. Patients in the non-randomized control
group were H. pylori-negative and received placebo.
Patients were stratiﬁed by endoscopic classiﬁcation of
reﬂux disease according to the Los Angeles (LA)
system.26
Patient recruitment
A total of 19 hospital- and oﬃce-based gastroenterology
practices participated in the study, from Austria (n¼ 2),
Germany (n¼ 10) and Switzerland (n¼ 7). Patients aged
above 18 that met the inclusion criteria were recruited:
(i) present with heartburn or acid regurgitation; (ii) at
least 8 weeks duration; (iii) at least three times a week;
and (iv) with at least moderate intensity, corresponding
to mild impairment in daily life and need for medication.
Exclusion criteria include history of previous oesopha-
geal or gastric surgery, alcohol or drug abuse, severe
organic or psychiatric disease, pregnancy or lactation,
women with child-bearing potential without contracep-
tive measures, allergy or contra-indication to study
medications, or need for concomitant medication.
Prior knowledge of H. pylori status and previous treat-
ment with PPIs were not exclusion criteria. The trial was
approved by ethical committees at each centre and writ-
ten informed consent was obtained.
Study participants underwent endoscopy. Patients
with Barrett oesophagus, malignancy, or peptic ulcer-
ation on endoscopy were excluded. Endoscopy and
biopsy were repeated at the end of the study. H.
pylori status was assessed by a 13C urea breath test at
recruitment and at the end of the study.27 Gastric biop-
sies (author MV) and breath test samples (author AL)
were forwarded to reference laboratories. Local inves-
tigators remained blind to the H. pylori status through-
out the study.
Randomization
Computer-controlled inclusion and randomization of
patients were operated by an independent study monitor
(PharmaPart, Thalwil, Switzerland). Patients that met
Schwizer et al. 227
entry criteria were randomized by a dynamic, centralized
procedure that ensured blinding to H. pylori status and
treatment group allocation. Probability of rejection was
computed such that the projected fraction of patients in
each group was constant at each point in time during the
study. This system ensured that the appropriate num-
bers of patients with LA grade 0, AB, or CD oesopha-
gitis on endoscopy were recruited and that a balanced
sample of patients was entered at each site.
Patients with evidence of H. pylori infection on 13C
urea breath test were randomized either to the anti-
biotics group for eradication or placebo (gastric hist-
ology was not considered). H. pylori-negative control
patients all received placebo. Because of the higher
prevalence of H. pylori-negative compared to H.
pylori-positive patients, a computerized early random
rejection scheme was applied that accepted one-third
initially and was dynamically adjusted to ensure
balanced recruitment throughout the entire study.
Prior to transferring data for analysis, monitors
removed all information on drug randomization and
H. pylori status from the database.
Study protocol
Once the centralized system had rejected or accepted
the patient, the local investigator was informed by
fax. If accepted, study medication was dispensed and
a central call centre was informed so that telephone
interviews could be arranged (no clinical details were
transferred). As outlined in the ﬂow chart (Figure 1),
patients were contacted by the call centre to assess
symptom severity before and after 8 weeks treatment
with esomeprazole and subsequently at 2-week intervals
until recurrence of reﬂux symptoms on two subsequent
occasions (relapse) or the completion of 32 weeks of
follow up. At the end of the study (i.e. relapse or 32-
week follow up), the patient underwent repeat endos-
copy and 13C urea breath test. Further management
decisions were based on clinical discretion.
Study medications
For H. pylori eradication, patients were randomized to
receive either amoxicillin 1000mg, and clarithromycin
500mg, administered twice daily for the ﬁrst 7 days
(antibiotics group), or identical placebo tablets (pla-
cebo group). Treatment of GORD with esomeprazole
(Nexium; AstraZeneca, Zug, Switzerland) was not ran-
domized. All patients received 20mg b.d. for 7 days
from study start, followed by 40mg o.d. for 49 days
to complete an 8-week course of esomeprazole.
This management has been proven eﬀective for H.
pylori eradication,28 oesophagitis healing, and
Randomization
Eradication treatment
+ Nexium 20mg bid Nexium 40mg od
Nexium 40mg od
Nexium 40mg od
Phone contact (interview) Phone contacts (interviews)
Screening/
Baseline
Treatment period
Day −4/−5 Day 0 Day 7 Day 56 Day 280
end of study
No Treatment
until relapse
Endoscopy
Hp tests,
Questionnaire
Placebo +
Nexium 20mg
bid No PPI medication
until relapse:
Rescue medication:
Gaviscon)
Placebo +
Nexium 20mg
bid
H. pylori pos.
H. pylori
neg. controls
Figure 1. Schematic flow chart of Erastrat study procedures.
PPI, proton pump inhibitor.
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symptom resolution.29 After acid suppression was with-
drawn, patients were provided with an alginate prepar-
ation (Gaviscon; Reckitt Benckiser, Slough, UK) as
rescue medication for recurrent symptoms.
Symptom assessment
The Eraﬂux questionnaire measures the frequency, dur-
ation, and intensity of reﬂux symptoms: heartburn,
regurgitation, chest or retrosternal pain, and dyspha-
gia.20 Relapse was deﬁned as recurrence of GORD
symptoms to an Eraﬂux score of 25 at two consecutive
interviews.25 The day of the ﬁrst interview was taken as
date of relapse.
Outcome measures
The primary objective of this study was to assess
whether H. pylori eradication treatment extends the
time to symptomatic relapse after withdrawal of PPI
therapy in patients with a clinical diagnosis of GORD.
In addition, the time to relapse in the twoH. pylori-posi-
tive study groups with the non-randomized H. pylori-
negative control group was compared. Data analysis
was performed with patients stratiﬁed according to
oesophagitis grade at inclusion. Secondary objectives
were to compare the eﬀect of H. pylori infection and
eradication on reﬂux oesophagitis and to compare the
pattern of gastric inﬂammation and atrophy in the two
H. pylori-positive treatment groups with the H. pylori-
negative control group at relapse. Outcome data was
analysed by ‘intention-to-treat’ (ITT) and ‘as treated’,
deﬁned by H. pylori status at relapse or the end of the
study (eradicated, non-eradicated, negative control).
Histology
Biopsies were obtained from the oesophagus, gastric
antrum, and corpus (midportion at the greater curva-
ture) with standard forceps at recruitment and at the
end of the study. Specimens were ﬁxed in 10% neutral
buﬀered formalin and stained with haematoxylin and
eosin and Alcian blue periodic Schiﬀ. Histology was
assessed by independent investigators (MV, RG) for
determination of H. pylori infection, presence of gastri-
tis, mucosal thickness, and density of parietal cells. H.
pylori gastritis and mucosal atrophy were graded
according to the Sydney System.30 Histologists were
not aware of clinical and endoscopic ﬁndings or treat-
ment allocation.
Data analysis
Clinical data was entered manually into an on-line
database. Data from early dropouts within the ﬁrst 8
weeks (i.e. during treatment with esomeprazole) were
not used. Data from dropouts during the 32-week
follow up (oﬀ treatment) are censored to the date of
the last telephone interview. Statistics were computed
with R.31 Two-sided tests were used throughout the
study; results are reported as signiﬁcant for p< 005.
Cross-tabulations were tested with a 2 test. Cox-
proportional hazard regression was used for estimation
and comparison of survival curves and to test the eﬀect
of covariates.32 95% conﬁdence intervals (CI) of esti-
mates were calculated. To test the hypothesis that
reduced inﬂammation in the gastric corpus is related
to reduced relapse hazard, a three-level variable was
deﬁned for each patient, with 0 for no change, 1 for
improvement, and 1 for deterioration, and was ana-
lysed by a generalized linear model.
The ITT analysis contained all patients who took at
least one medication tablet. The as-treated subgroup
included patients with complete information from gas-
tric biopsies and 13C breath test at recruitment and at
the end of study. No gender-speciﬁc eﬀects were present
at baseline (Table 1). No breakdown for smoking, alco-
hol, or non-steroidal antinﬂammatory drugs (NSAID)
consumption was done, because the numbers of
patients that smoked, consumed >20 g alcohol/day or
took NSAID were too low. To assess the eﬀect of
oesophagitis on outcomes, subjects were stratiﬁed by
Table 1. Baseline characteristics of patients recruited into Erastrat study
n Min Q1 Median Q3 Max
Placebo Age (years) 98 21 39 50 60 81
BMI (kg/m2) 97 19 24 27 30 39
Antibiotics Age (years) 100 20 40 49 57 75
BMI (kg/m2) 100 19 25 27 30 36
Control Age (years) 113 19 41 50 61 71
BMI (kg/m2) 112 18 24 26 30 41
There were no differences in demographic or clinical parameters between H. pylori-positive and -negative patients.
BMI, body mass index.
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oesophagitis grade. A secondary analysis compared
outcome of patients with LA grade 0A and BCD endo-
scopic ﬁndings. This grouping was based on ﬁndings of
longitudinal studies of GORD natural history and to
allow direct comparison to previous publications.19,33
The sample size was based on a Monte Carlo resam-
pling of the patients enrolled in the Eraﬂux study.20
These calculations determined that with 60 patients in
each study group and a hazard ratio (HR) of symptom-
atic relapse of 1.5 between the patient groups, a test
power of 0.9 at an type I error rate of 0.05 can be
achieved for the primary endpoint. Based on these cal-
culations and allowing for a 40% dropout rate, the
study aimed to recruit 318 patients.
Results
This multicentre trial involved eight teaching hospital-
and 11 oﬃce-based practices or district hospitals. The
median number of patients assessed and recruited per
type of centre was 18 and 10 patients, respectively.
When terminated because of time constraints, 589
patients had been assessed of whom 581 were eligible.
After randomized exclusion of excess H. pylori-negative
patients, 311 were recruited (62% from oﬃce-based
practices or district hospitals).
Study population
The baseline statistics of 311 patients included in the
ITT analysis are in Table 1. In the study, 169 females
and 142 males (54 and 46%) participated.Median age
was 50 years (range 19–81), and six patients were older
than 70 years. At study entry, endoscopy revealed LA
grade 0 (41%, n¼ 127), A (23%, n¼ 71), B (25%,
n¼ 77), and CD (11%, n¼ 36) reﬂux oesophagitis.
Patient progression
Of 581 eligible patients, 198 (34%) were H. pylori-
positive on 13C urea breath test. Of 383 H. pylori-
negative patients, 113 were randomly selected to serve
as controls. The progress of the 311 patients recruited
through the Erastrat study is detailed in Figure 2.
Initial treatment with 8-week esomeprazole did not
improve reﬂux symptoms in 35 (11%) patients. There
was no indication that the likelihood of treatment fail-
ure was inﬂuenced by oesophagitis grade, baseline H.
pylori status or allocation to study treatment. Adverse
events were reported by 76 patients (antibiotics 25, pla-
cebo 23, control 28), leading to the withdrawal of 20
patients. Of these 13 were considered due to the study
medication, most commonly nausea or diarrhoea
during H. pylori eradication therapy. Following with-
drawal of esomeprazole, in the 223 patients that had an
initial response to acid suppression and continued in
the study, symptomatic relapse was reported by 134
patients (60%) during the 32-week follow-up period.
The success of H. pylori eradication was 82% by 13C
urea breath test at time of relapse or at 32-week follow
up. At the end of the study (as treated), 84 patients were
H. pylori-positive (placebo and failed eradication), 55
Assessed
589
Eligible
581
Inelligible
8
Non-Relapse
18
Non-Relapse
30
Non-Relapse
30
Antibiotics
100
Placebo
98
Hp Positive
198
Hp Negative
383
RanEx
270
Control
113
No Result
40
No Result
31
No Result
28
Relapse
55
Relapse
37
Relapse
42
Figure 2. CONSORT diagram of Erastrat study: ITT analysis.
Hp, H. pylori; RanEx, H. pylori-negative patients randomly excluded from study; No result, dropouts during treatment phase, treatment
failures, and dropouts on follow up.
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were H. pylori-negative (successful eradication), and 59
were H. pylori-negative controls.
Effect of H. pylori status and eradication therapy
on relapse of reflux symptoms
Patients in the twoH. pylori-positive groups had a simi-
lar rate of relapse at 32-week follow up (Figure 3). H.
pylori eradication therapy had no eﬀect on relapse
hazard during the 32-week follow up (HR antibiotic
vs. placebo 1.15, 95% CI 0.74–1.8; p¼ 0.5). H. pylori-
positive patients, treated by antibiotics or placebo, had
a lower probability of relapse compared to the H.
pylori-negative control group (HR 0.6, 95% CI 0.43–
0.85; p¼ 0.004). Subgroup analysis showed that the
non-randomized H. pylori-negative control group had
an increased risk of relapse compared to bothH. pylori-
positive groups (HR against placebo 1.79, 95% CI
1.18–2.70; against antibiotics 1.54, 95% CI 1.03–2.33).
This result is not altered by correction for age and sex.
Time to relapse from the smaller as-treated subset of
patients is not diﬀerent from that of the ITT subset.
Effect of oesophagitis status on relapse of reflux
symptoms
Stratiﬁcation of time to relapse analysis by endosopic
ﬁndings reveals two distinct patterns (Figure 4,
Table 2).: All patients in the H. pylori-negative control
group and patients with moderate-severe oesophagitis
(LA grade BCD) had a probability of relapse at 32
weeks of 71% or above. In contrast, irrespective of
eradication (p¼ 0.6),H. pylori-positive patients without
oesophagitis or with mild oesophagitis (grade A) had 50
and 45% probability of relapse, respectively (Table 2).
The HR for relapse between patients with oesophagitis
BCD compared to 0A was 2.1 (95% CI 1.5–3.0).
Increased time to relapse in non-eradicated H. pylori-
positive compared to H. pylori-negative controls was
observed for patients with LA OA (HR 0.41, 95% CI
0.23–0.71; p¼ 0.002), but not those with LA BCD (HR
0.97, 95% CI 0.52–1.80).
In the patient group with oesophagitis, repeat endos-
copy at the end of the study revealed that LA grade had
0
0.0
0.2
0.4
N
on
-R
el
ap
se
 P
ro
ba
bi
lity
0.6
0.8
1.0
30 60 90 120
Days
150
Subset: ITT
180 210 240 270
Figure 3. Cox regression.
The proportion of patients with sustained remission of reflux symp-
toms after 8 weeks of PPI therapy was similar in H. pylori-positive
patients irrespective of treatment allocation to antibiotic (Anti) or
placebo (Pla), but greater in the H. pylori-negative control (Con)
group.
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Figure 4. Cox regression stratified according to endoscopic
findings.
The proportion of patients with sustained remission of reflux symp-
toms after 8 weeks of PPI therapy. H. pylori status had important
effects on the risk of relapse in patients with endoscopy-negative
reflux disease or LA grade-A reflux oesophagitis; however H. pylori
status had no effect on the relatively high risk of relapse in patients
with more severe, LA grade BCD reflux oesophagitis.
Table 2. Probability of relapse at 32 weeks by degree of
oesophagitis and patient group
Oesophagitis
LA grade Treatment
Symptomatic
relapse at 32 weeks
0 or A H. pyloriþ antibiotics 50 (37–65)
H. pyloriþ placebo 45 (32–60)
H. pylori  control 77 (64–88)
B, C or D H. pyloriþ antibiotics 74 (58–88)
H. pyloriþ placebo 71 (53–87)
H. pylori  control 72 (58–85)
Values are % (95% CI).
LA, Los Angeles.
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improved for 59 (34%), deteriorated for 22 (13%)
patients, and was unchanged for 91 patients (53%).
The improvement was greater in the patients with
severe reﬂux oesophagitis. Comparing patients with
and without a symptomatic relapse, those that remained
symptom free tended to have a greater improvement in
oesophagitis grade at the end of the study (p¼ 0.089).
Histology
All 311 patients enrolled into the study had biopsies
obtained from the oesophagus, gastric antrum and gas-
tric corpus at baseline, and 173 (56%) had histology
samples also taken at the end of the study.
Oesophageal histology reveals no diﬀerence at base-
line between H. pylori-positive and -negative patients in
terms of inﬂammation, dilated intracellular spaces,
length of regenerative papillae, or thickness of the base-
ment membrane (all p> 0.1). Neutrophilic (p¼ 0.093)
and eosinophilic (p¼ 0.011) inﬁltration increased with
severity of reﬂux oesophagitis. Oesophageal histology
did not predict primary treatment outcome (i.e.
response of reﬂux symptoms to 8 weeks of esomepra-
zole treatment).
At baseline moderate or marked gastritis deﬁned by
the Sydney Classiﬁcation was much more prevalent in
H. pylori-infected patients than in H. pylori-negative
controls (143/198, 72%, vs. 4/103, 4%; p< 0.0001)
and the gastric mucosa was thicker (diﬀerence
130.9mm, 95% CI 27.2–158.1 mm; p¼ 0.0063). There
was no diﬀerence in the number of parietal cells per
high-powered ﬁeld (hpf) between H. pylori-positive
and -negative patients (diﬀerence 5.3/hpf, 95% CI
1.9 to 3.4/hpf; p¼ 0.56). After successful H. pylori
eradication and 8 weeks of esomeprazole, the number
of patients with moderate or marked gastritis fell from
77% to none, whereas 66% had persistent gastritis in
those H. pylori-positive patients that either failed eradi-
cation or received placebo (p< 0.001). There was a
trend between the improvement in gastritis following
H. pylori eradication and the risk of symptomatic
relapse (p¼ 0.09) but there was no evidence that the
number of parietal cells per high-powered ﬁeld is a pre-
dictor of relapse (p¼ 0.39)
Discussion
This large, multicentre trial evaluated the eﬀect of H.
pylori infection and eradication on reﬂux symptoms
and endoscopic ﬁndings in patients presenting with
symptoms of GORD. Patients received H. pylori eradi-
cation therapy or placebo with esomeprazole followed
by 8 weeks of PPI therapy using methodology of
proven eﬃcacy,28,29 which is consistent also with guide-
lines for treatment of these conditions.1,34 At the end of
this treatment period, eﬀective relief of reﬂux symptoms
was achieved in 89% of patients and a repeat 13C urea
breath test conﬁrmed successful H. pylori eradication in
82%, both consistent with previous reports from simi-
lar populations.28,29 The primary outcome of the ran-
domized controlled trial is that H. pylori eradication
therapy has no eﬀect on the relapse hazard (i.e. cumu-
lative probability of relapse) for reﬂux symptoms
during 32 weeks of follow up after withdrawal of acid
suppression (Figure 3). The risk of symptomatic relapse
is reported as 50 and 45% in the antibiotic and placebo
groups, respectively, with no diﬀerence between groups
(HR 1.15, 95% CI 0.74–1.8; p¼ 0.5). This result was
not altered by correction for age, sex, or other potential
confounding factors included in the analysis.
Important additional information was obtained
when patients were stratiﬁed according to grade of
oesophagitis (Figure 4). For patients with endoscopy-
negative reﬂux disease or mild oesophagitis (grade 0 or
A, n¼ 196), the relapse hazard in the H. pylori-negative
control group was signiﬁcantly greater than that of the
eradicated patients (HR 2.13, 95% CI 1.23–3.70;
p¼ 0.006), with a relapse hazard at 32 weeks of 77
and 50%, respectively. Whereas for patients with mod-
erate to severe oesophagitis (grade B, C, or D, n¼ 115),
symptomatic relapse was rapid and H. pylori status had
no eﬀect on relapse hazard (HR 0.93, 95% CI 0.52–
1.69; p¼ 0.8). The ﬁndings were not altered by H.
pylori eradication in either subgroup. Thus, the pres-
ence of H. pylori infection prolongs the time to symp-
tomatic relapse in patients with absent or mild
endoscopic disease, but other factors, likely related to
disruption of the oesophago-gastric junction and high
levels of oesophageal acid exposure,1 determine the nat-
ural history of disease in patients with more severe
reﬂux oesophagitis.
These ﬁndings are in agreement with epidemiological
reports that the risk of reﬂux symptoms and mucosal
disease is reduced in H. pylori-positive patients.
Raghunath et al.9 undertook a systematic review of
20 studies including more than 4000 patients and
found that the odds ratio for H. pylori prevalence in
GORD patients was 0.60 (95% CI 0.47–0.78).
However, the results diﬀer from previous randomized
controlled trials which report little or no diﬀerence in
time to relapse between the H. pylori-positive and
–negative groups.19,20 The current study had a similar
design but important strengths. First, a much larger
study population. Second, inclusion of patients across
the spectrum of GORD allowed stratiﬁcation of results
with severity of oesophagitis. Third, recruitment of
patients with typical reﬂux symptoms from multiple
centres, with the majority from oﬃce-based practices
and district hospitals. Patients presenting to tertiary
care have a high rate of somatization and psychosocial
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morbidity and these factors may be more closely related
to treatment outcomes than disease activity.35 The
excellent response (90%) to initial PPI therapy and
the high ‘ongoing remission’ rate at 32 weeks (50%)
oﬀ medication in the current study is higher than that
reported by previous randomized controlled trials
based in tertiary care and may be more representative
of those sampled in epidemiological and community-
based studies in which similar eﬀects of H. pylori infec-
tion in GORD were found.
The biological mechanism underlying the relatively
rapid relapse of reﬂux symptoms in H. pylori-negative
controls compared to H. pylori-positive patients is not
established. One explanation for the ‘protective’ eﬀect
of H. pylori infection in GORD is persistent reduction
in gastric acid secretion. Rebound acid hypersecretion
and reﬂux symptoms have been reported in healthy H.
pylori-negative subjects and also H. pylori-negative
reﬂux patients after discontinuation of omeprazole;36,37
in contrast, many H. pylori-positive patients show per-
sistent acid suppression after eradication.36 Direct
measurements of acid secretion were not performed;
however, the results are consistent with these observa-
tions. H. pylori status has no eﬀect on the success of
initial PPI therapy and yet, during 32 weeks of follow
up after withdrawal of acid suppression, H. pylori-
negative patients have a higher risk of relapse than H.
pylori-positive patients irrespective of allocation to
eradication therapy or placebo. Histology shows a dra-
matic improvement in gastritis in H. pylori-positive
patients following successful eradication therapy and
resolution of corpus inﬂammation is associated with a
trend to symptomatic relapse. Over time, recovery of
acid-secreting capacity may occur in patients with gas-
tric mucosal atrophy as parietal cell mass recovers;38,39
however, in this study, very few H. pylori-positive
patients had mucosal atrophy and there was no diﬀer-
ence in mucosal thickness or parietal cell numbers
between H. pylori-positive and -negative patients at
baseline or at the end of the study. These results
imply that the reduction in acid secretion with H.
pylori infection is caused by other mechanisms;
for example, downregulation of parietal cell H,K-
ATPase expression in gastric mucosa by H. pylori cag
gene products that signiﬁcantly inhibiting acid
secretion.40,41
The study population was under 70 years old. It is
possible that results may be diﬀerent in an older popu-
lation with a greater proportion of gastric atrophy, and
also in speciﬁc patient groups, such as those with duo-
denal ulcer14,15 and with strains ofH. pylori infection or
host inﬂammatory responses (e.g. interleukin 1b) that
powerfully inhibit acid secretion.42 Patients were diag-
nosed and recruited on the basis of typical reﬂux symp-
toms rather than ambulatory pH-impedance
monitoring; however, symptom-based diagnosis and
the response to therapeutic trials are considered accept-
able surrogates in most clinical settings.34 Overall,
slightly less patients entered the study than planned
(311/318, 98%); however, suﬃcient numbers were
attained for a robust ITT analysis of primary and sec-
ondary endpoints. Nevertheless, it should be noted that
the conﬁdence intervals of the ITT analysis are fairly
wide, thus a small eﬀect of eradication therapy on treat-
ment outcome cannot be excluded or could become
apparent with longer follow up. Findings from the
as-treated analysis were not qualitatively diﬀerent;
however, the diﬀerences between groups were less pro-
nounced because repeat 13C breath tests and gastric
histology were available for only 56% of the total
study population. Incomplete data collection also
reduced the statistical power to determine the eﬀects
of changes in histological biomarkers following H.
pylori eradication on relapse hazard.
In conclusion, H. pylori eradication therapy has no
impact on the success of PPI therapy for GORD or the
risk of symptomatic relapse after withdrawal of acid
suppression. Instead, the presence of H. pylori infection
at study entry decreases the risk of symptomatic
relapse, especially in patients with absent or mild muco-
sal disease. This is the ﬁrst time that the protective
eﬀect of H. pylori infection in GORD described by epi-
demiologists has been demonstrated in a prospective,
clinical study.
These ﬁndings have direct implications for practice.
Clinicians and patients can be reassured that the short-
to mid-term management of GORD patients can be
focused on symptom control, independent of the deci-
sion to investigate and treat H. pylori infection. Indeed,
it will often be easier to discontinue PPI therapy in
reﬂux patients with H. pylori infection. If long-term
PPI therapy is required, then H. pylori infection can
be identiﬁed and eradication therapy prescribed; how-
ever, again, this can be performed without undue con-
cern that this will exacerbate GORD symptoms or
mucosal disease.
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